World-first clinical trial confirms exercise improves survival for colon cancer Français
A Canadian Cancer Society-funded trial reveals that guided exercise can save and prolong lives by reducing risk of cancer recurrence and second cancers
TORONTO, June 1, 2025 /CNW/ - A groundbreaking clinical trial funded by the Canadian Cancer Society (CCS) shows that physical activity can significantly improve outcomes for people with colon cancer. Researchers say the study is the first in the world to use structured exercise to increase cancer survival.
The trial results, presented today at the American Society of Clinical Oncology annual conference and published in the New England Journal of Medicine, have the potential to change clinical practice. They show that, when incorporated into cancer care for people with colon cancer, a structured exercise program reduces the risk of cancer recurrence and of new primary cancers developing.
"Our findings show that exercise is no longer just a quality-of-life intervention for cancer patients that can be offered when and where possible," says study co-chair Dr Kerry Courneya, a professor of kinesiology at the University of Alberta and Canada Research Chair in Physical Activity and Cancer. "It is a treatment for colon cancer that must be made available to all patients."
Colorectal cancer is the second leading cause of cancer death in Canada. Last year, an estimated 25,200 Canadians were diagnosed with colorectal cancer and 9,400 people died from it. To improve outcomes, a team led by Dr Courneya and Dr Chris Booth – study co-chair, medical oncologist at Kingston Health Sciences Centre and professor of oncology at Queen's University – has been working with the Canadian Cancer Trials Group (CCTG) on this first-of-its kind trial.
The 17-year international trial involved 889 people, all of whom had been diagnosed with and treated for colon cancer. After having surgery and chemotherapy, participants were given a 3-year structured exercise program or standard health education materials that are currently given to patients. Each participant in the exercise program chose their own forms of moderate-intensity exercise – from walking to pickleball – with the goal of adding 2.5 hours of exercise per week to their regular activity schedule. The outcome: those who received the exercise program had a 28% lower risk of recurrence and new cancers and a 37% lower risk of death.
"This is the first clinical trial in the world designed to answer whether exercise can improve cancer survival, and the results are clear," says Dr Booth. "The next step is to put this into practice. That means health systems will need to invest in behaviour support programs as part of standard care."
The researchers are currently conducting a comprehensive health economic analysis. According to Dr Booth, they anticipate that the program will be "remarkably cost-effective compared to many new cancer drugs," making it sustainable for health systems.
Terri's story
Terri Swain-Collins was diagnosed with stage 3 colon cancer in 2021 after a screening test led to further investigation. Following treatment including surgery and chemotherapy, she was invited to join Dr Booth and Dr Courneya's clinical trial. During the trial, she worked closely with a physiotherapist to establish and maintain a fitness routine personalized to her needs.
"One of the biggest benefits was having a semi-structured routine that works for my lifestyle with someone to hold me accountable," says Terri. "Simply being told to exercise by a physician wouldn't have been enough to get me to where I am today; having someone walk alongside me, guide me and check in regularly was what truly made it possible."
Now, 3 years later, Terri continues to walk 3 times a week, feels fit and remains cancer-free. She says she is grateful for the impact of the program on her health and well-being.
"By bridging the gap between bold ideas and routine practice, clinical trials are essential to driving research progress that can benefit patients," says Dr Stuart Edmonds, Executive Vice President, Mission, Research and Advocacy at CCS. "The results of this trial have the potential to save and improve lives for the tens of thousands of people in Canada affected by colorectal cancer each year, and we are proud our donors enabled us to support it."
The international study co-chair was Dr Janette Vardy, from The University of Sydney (Australia) with funding from National Health and Medical Research Council. The UK team was led by Dr Victoria Coyle at Queen's University of Belfast, supported by Cancer Research UK.
About the Canadian Cancer Society
The Canadian Cancer Society works tirelessly to save and improve lives. We raise funds to fuel the brightest minds in cancer research. We provide a compassionate support system for all those affected by cancer, across Canada and for all types of cancer. Together with patients, supporters, donors and volunteers, we work to create a healthier future for everyone. Because to take on cancer, it takes all of us. It takes a society.
Help us make a difference. Call 1-888-939-3333 or visit cancer.ca today.
About the Canadian Cancer Trials Group
The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I–III trials to test anti-cancer and supportive therapies at over 85 hospitals and cancer centres across Canada. From their operations centre at Queen's University, CCTG has supported more than 600 trials enrolling 100,000 patients from 40 countries on 6 continents through a global network of 20,000 investigators and clinical trial staff. CCTG is the Canadian Coordinating Clinical Trial Network for the US NCTN and is a national program of the Canadian Cancer Society. CCTG's aim is to improve survival and quality of life for all people with cancer. Learn more at cctg.ca.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
6 hours ago
- Vancouver Sun
B.C. son of woman who inspired assisted dying law chooses to die on his own terms
Price Carter is planning to die this summer. The 68-year-old Kelowna man has been diagnosed with stage 4 pancreatic cancer. He knows it will take his life eventually. Before it does, he intends to die on his own terms with his family at his side. 'I was told at the outset, 'This is palliative care, there is no cure for this.' So that made it easy,' he said from his home. Carter said he's always known that medical assistance in dying would be an option 'that I would exercise if I could, if needed to.' Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. He has that option, in large part, because of his mother. Kay Carter's name is on the landmark Supreme Court of Canada case that gave Canadians the right to choose a medically assisted death just over a decade ago. Price has finished a first assessment and said he expects the second assessment deeming him eligible for the procedure to be completed this week. He spoke openly and calmly about his final days and his decision to end his life. 'I'm at peace with this, I truly am, and I would have been years ago,' he said. It's been nearly a year since he first started experiencing symptoms and got a diagnosis. Until a couple of months ago, he said, he was swimming and rowing. He and his wife Danielle went golfing recently, playing best ball. 'She dragged me down that course,' he said with a laugh. But his energy is starting to fade. He knows how he wants the next step to unfold. It was more than 15 years ago that Price, along with his sisters Marie and Lee and his brother-in-law Hollis, surreptitiously made their way to Switzerland to be with their mother on her final day. The 89-year-old was living with spinal stenosis and chose to go to a non-profit facility that provided medically assisted death. She became the 10th Canadian to do so. At the time, assisted death was illegal in Canada. Kay Carter wrote a letter explaining her decision and her family helped draft a list of about 150 people to send it to after she died. She couldn't tell them her plans in advance because of the risk that Canadian authorities would try to stop her from going to Switzerland, or prosecute the family members who helped her. When she got to the Dignitas facility, she finalized the paperwork, settled in a bed and chased down the barbiturate that would stop her heart with Swiss chocolate. 'When she died, she just gently folded back,' Price said. After a few minutes, one of the attendants from the facility walked over to the door, 'and the curtains billow out, and she says, 'There, her spirit is free,'' he said. 'If I was writing the movie, I wouldn't change that.' He said the memory makes him cry today, though not from sadness. The cancer, and the treatment, have made him emotional — the experience itself was beautiful. 'I wish for my children that they can see my death like I did my mom's,' he said. He said wants his wife, Danielle, and his kids to be there. His children — Lane, Grayson and Jenna — live in Ontario. They're all busy, he said, so when the time is right he'll try to find a date that works for everyone. For now, he's doing a lot of reading. 'I'm just gonna keep hanging on, day by day, and enjoying my Danielle.' The Carter family had a long road after Kay's death in January 2010. Her eldest daughter Lee was the driving force behind taking the case to the Supreme Court, which issued a unanimous decision in early 2015 that struck down sections of the Criminal Code that made it illegal to help someone end their life. In 2016, the federal government passed legislation that created the country's regime for medical assistance in dying and made it legal for people whose deaths were 'reasonably foreseeable' to apply for an assessment. After a 2019 ruling in the Quebec Superior Court found it was unconstitutional to restrict assisted dying to people whose deaths were reasonably foreseeable, the Liberal government updated the law in 2021. That update included a controversial clause that would allow people suffering solely from a mental disorder to be considered eligible for an assisted death. The proposed change caused widespread worry among provinces and some mental health professionals, and has now been delayed until March 2027. In the meantime, Health Canada has been studying what Canadians think of allowing people to ask for medical assistance in dying through an advance request. Advance requests would allow people with Alzheimer's, dementia, or other degenerative conditions to make the application and decide when they'd like to end their lives. Price Carter said that change 'is such a simple thing to do.' 'We're excluding a huge number of Canadians from a MAID option because they may have dementia and they won't be able to make that decision in three or four or two years. How frightening, how anxiety-inducing that would be,' he said. He admitted to feeling frustrated at the pace of change, though he said he knows his 'laissez-faire' attitude toward death is uncommon. Helen Long, the president of Dying With Dignity Canada, said numerous federal consultations have shown there's broad support for advance requests dating back to 2016. 'We're continuing to advocate and ask our new government … to make advance requests legal for Canadians,' she said. Quebec has passed legislation to allow people with serious and incurable illnesses to apply through an advance request for a medically assisted death in the event that they become incapacitated. Marjorie Michel, who was recently named health minister in Prime Minister Mark Carney's new government, said it's a question of balance. 'It's so personal for people, and I think in some provinces they are not there yet,' she said. But when asked if the government plans to allow advance requests, she deferred to her colleague in the Justice Department. A spokesperson for Justice Minister Sean Fraser said Michel would be best positioned to respond. Health Canada is set to release a report with the key findings from its consultations on the matter this spring. Medical assistance in dying is becoming more common in Canada. In 2023, the latest year for which national statistics are available, 19,660 people applied for the procedure and just over 15,300 people were approved. More than 95 per cent of those were people whose deaths were considered reasonably foreseeable. Price Carter said he wants to talk about his condition because he wants Canadians to talk about death, as uncomfortable as it is. 'The more conversations we can spawn around kitchen tables, the better,' he said. 'We're all going to die. It's part of the condition of living. And yet we do ignore this, to our peril.'
Cision Canada
11 hours ago
- Cision Canada
New Canada Research Chair at the UQAT: reduce the environmental impacts of mining operations in cold regions
ROUYN-NORANDA, QC , June 2, 2025 /CNW/ - The Université du Québec en Abitibi-Témiscamingue (UQAT) is proud to announce the award of a new Canada Research Chair. Last March, the Minister of Innovation, Science and Industry, the Honourable François-Philippe Champagne, announced the creation of the Canada Research Chair in Geoenvironmental Engineering of Mine Waste in Cold Regions to be held by Vincent Boulanger-Martel, Professor at the Research Institute of Mines and Environment (RIME). Tier 2 Chairs are awarded to outstanding emerging researchers considered by their peers to have the potential to become leaders in their field. Provide much-needed expertise to the Canadian mining community Advances in technology and the world's growing demand for diverse natural resources have led to an increase in mining activity across the country and pushed mining operations farther away from populated mining regions. As a result, there is an increasing number of mining projects being developed in northern and remote regions of Canada. The development of such mining projects brings numerous unique technical, environmental, and social acceptability challenges. Curently, only few solutions have been specifically developed to overcome the challenges associated with the severe seasonal freezing and thawing as well as permafrost* conditions of northern Canada. The research program of this Canada research chair aims to develop practical, climate-resilient mine waste management and reclamation solutions specifically designed for cold regions to reduce the impacts of mining activities. This program will therefore help the mining industry, government agencies, and consultants to better manage mine waste, reduce environmental impacts, and protect fragile ecosystems of these regions. "I aim to undertake cutting-edge research ranging from fundamental experimentation to laboratory and field testing, as well as numerical modeling," says the chairholder, Vincent Boulanger-Martel. Several technological advances are proposed in cold region experimental geotechnics and geoenvironmental engineering, advanced numerical modelling, remote sensing, and monitoring applied to mine waste management and reclamation. The work is geared towards solving practical, concrete problems faced by the mining industry, governmental agencies and consulting firms in Canada. The results of this chair will enhance our ability to sustainably design and manage critical mining structures under conditions specific to cold regions, from operation to post-closure. Professor Vincent Boulanger-Martel is receiving $600,000 in funding from the Canada Research Chairs Program, as well as $322,500 from the Canada Foundation for Innovation for the acquisition of new laboratory equipment. The Research Institute of Mines and Environment (RIME) With more than $8 million in research annually the RIME boasts an internationally-recognized team of experts, with more than fifteen specialized laboratories and a vast network of industrial test sites. Its work is carried out within the framework of projects led by several scientific groups and research chairs, fostering a collaborative, multidisciplinary approach. RIME also plays a key role in the training of highly qualified personnel, ready to meet the challenges of the mining sector and actively contribute to the sustainable development of communities. UQAT ranks first in Canada in terms of research intensity per professor among Canadian universities primarily active at the undergraduate level (RE$EARCH Infosource Inc., 2024). * Ground that remains at or below 0°C for at least two consecutive years. SOURCE Université du Québec en Abitibi-Témiscamingue (UQAT)
Cision Canada
14 hours ago
- Cision Canada
Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025
- , June 3, 2025 /CNW/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's disease and Alpha-1 antitrypsin deficiency, announced today its participation at the GBA1 Meeting 2025, being held June 5-7, 2025 in Montreal, Canada. Congruence is also a sponsor of the meeting. "We are pleased to present our science on novel GCase activators and correctors for GBA1 Parkinson's Disease at this important scientific congress," said Sharath Hegde, Ph.D., Chief Scientific Officer of Congruence. "We are developing small molecules discovered leveraging our Revenir ™ platform that are designed to correct biological deficits resulting from mutations in the GBA1 gene. We look forward to advancing the most potent orally active and brain-penetrant allosteric GCase activator and corrector molecules for future evaluation in people living with Parkinson's disease." Oral presentation details: Title:" Discovery of Small Molecule Therapeutics for GBA1-PD" Session: 2- Small Molecules Targeting GBA1 Session Date and Time: Thursday, June 5 th, 2025, 11:40am-12:00pm Presenting Author: Indranath Ghosh, PhD, Director, Medicinal Chemistry, Congruence Therapeutics About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two recently executed multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases. For more information, please visit Media Contact Amy Conrad Juniper Point [email protected] 858-366-3243 SOURCE Congruence Therapeutics
